8-K: The Oncology Institute Reports Strong Revenue Growth but Declining Gross Profit in Q1 2024

The Oncology Institute (TOI) announced a 24.2% increase in revenue for the first quarter of 2024, alongside a decrease in gross profit and an adjusted EBITDA loss.

Summary

• The Oncology Institute (TOI) reported its financial results for the first quarter of 2024, showing a significant increase in revenue but a decrease in profitability.
• Consolidated revenue reached $95 million, a 24.2% increase compared to the same quarter last year, driven by growth in patient services, dispensary, and clinical trials.
• Gross profit decreased by 15.1% to $12 million, with a gross margin of 12.6%, down from 18.5% in the prior year quarter, primarily due to cost management fluctuations of oral and IV drugs.
• The company experienced a net loss of $19.9 million, an improvement from the $30.0 million loss in the prior year quarter, due to a goodwill impairment charge in Q1 2023 that did not occur in Q1 2024.
• Adjusted EBITDA was a loss of $10.9 million, compared to a loss of $7.4 million in the prior year quarter.
• TOI reaffirmed its full-year 2024 guidance, projecting revenue between $400 and $415 million, gross profit between $68 and $79 million, and an adjusted EBITDA loss between $8 and $18 million.

Sentiment

Score: 5

Explanation: The document presents mixed results with strong revenue growth offset by declining profitability and increased losses. The reaffirmation of guidance provides some stability, but the overall sentiment is neutral to slightly negative due to the profitability concerns.

Positives

• The company achieved a 24.2% increase in consolidated revenue year-over-year, reaching $95 million.
• Dispensary revenue saw a significant increase of 63.7% compared to the same quarter last year.
• Clinical trials and other revenue increased by 50.9% year-over-year.
• Net loss improved by $10.1 million compared to the prior year quarter.
• The company successfully integrated its first capitated risk contract directly with a health plan.
• TOI signed a record 7 new capitation and value-based contracts in a single quarter.
• The number of scripts dispensed increased by 70% compared to the prior year quarter.
• Selling, general and administrative expenses decreased as a percentage of revenue, from 37.8% to 30.1%.

Negatives

• Gross profit decreased by 15.1% compared to the prior year quarter, reaching $12 million.
• Gross margin decreased from 18.5% to 12.6% year-over-year.
• Adjusted EBITDA was a loss of $10.9 million, which is worse than the $7.4 million loss in the prior year quarter.
• The company reported a net loss of $19.9 million for the quarter.

Risks

• The company's financial performance is subject to risks and uncertainties, including those disclosed in its filings with the SEC.
• The outlook does not account for unanticipated developments or changes in the operating environment.
• The company's outlook assumes a largely reopened global market, which could be negatively impacted by closures or restrictive measures.
• Fluctuations in the cost management of oral and IV drugs are impacting gross profit.
• The company's ability to achieve its financial guidance is subject to various risks and uncertainties.

Future Outlook

TOI reaffirms its full-year 2024 guidance, projecting revenue between $400 and $415 million, gross profit between $68 and $79 million, and an adjusted EBITDA loss between $8 and $18 million. The outlook assumes a largely reopened global market.

Management Comments

• Daniel Virnich, CEO of TOI, stated that he is very pleased with the company's performance in the first quarter of 2024, citing strong revenue growth and reduced SG&A.
• The CEO highlighted the full-risk capitated contract in South Florida as a significant milestone for TOI.
• Management believes the company's ability to grow top line through new value-based partnerships and expansion of the oral specialty drug business lays the groundwork for continued success in 2024 and beyond.

Industry Context

The Oncology Institute's focus on value-based care and capitated contracts aligns with the broader industry trend towards shifting away from fee-for-service models. The expansion of their oral specialty drug business also reflects the growing importance of this area in oncology care.

Comparison to Industry Standards

• While TOI's revenue growth of 24.2% is strong, the decrease in gross profit and adjusted EBITDA loss are concerning when compared to other established healthcare providers.
• Companies like US Oncology and McKesson Specialty Health, which also operate in the oncology space, typically aim for higher gross margins and positive EBITDA.
• The success of TOI's capitated contracts will be crucial for long-term profitability, as these models require efficient cost management and predictable patient outcomes.
• TOI's growth in dispensary revenue is notable, but the slight decrease in average revenue per filled prescription suggests potential pricing pressures or changes in the mix of drugs dispensed.
• The company's focus on expanding its clinic network and provider base is consistent with industry trends, but the financial impact of these investments needs to be carefully monitored.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the decrease in gross profit and increased adjusted EBITDA loss, despite the strong revenue growth.
• Employees may be impacted by the company's cost management efforts.
• Patients may benefit from the expansion of value-based care and access to more clinics.
• Suppliers may see increased demand due to the growth in dispensary revenue.
• Creditors will be monitoring the company's financial performance and ability to meet its obligations.

Next Steps

• TOI will host a conference call on May 14, 2024, to discuss the first quarter results and management's outlook.
• The company will continue to focus on expanding its value-based care contracts and oral specialty drug business.
• TOI will monitor the impact of its recent acquisitions and partnerships on its financial performance.

Key Dates

Keywords

Oncology, Healthcare, Financial Results, Revenue, Gross Profit, EBITDA, Capitation, Value-Based Care, Dispensary, Clinical Trials